mardi 8 janvier 2019

Onco Actu du 8 janvier 2019

1. BIOLOGIE

New insights into a rare type of cancer open novel avenues of study [Karolinska Institutet]

3.1.1 PRÉVENTION - TABAC - E-CIGS

Flavored tobacco use rising in U.S. kids as vaping takes off [Reuters]

4.10 DÉP., DIAG. & PRONO. - FDA, EMA, NICE,...

Statement from FDA Commissioner Scott Gottlieb, M.D., on the agency’s new actions under the Pre-Cert Pilot Program to promote a more efficient framework for the review of safe and effective digital health innovations [FDA]

4.5 DÉP., DIAG. & PRONO. - COLORECTAL

Hopkins Researchers ID New Biomarker for Colorectal Cancers [Johns Hopkins]

4.7 DÉP., DIAG. & PRONO. - COL DE L'UTÉRUS

Mayo researchers find ‘unacceptable low’ cervical cancer screening rates [May Clinic]

5.12 IMMUNOTHÉRAPIES

Could Immunotherapy Offer a Cure for Cancer? [NY Times]

5.12.1 IMMUNOTHÉRAPIES - PARTENARIATS

Sanofi pays Regeneron $462M to exit immuno-oncology R&D pact [Fierce Biotech]

JPM19: Sanofi zeroes in on bispecifics in reworked Regeneron deal [Biopharma Dive]

bluebird bio and Inhibrx Announce Collaboration to Research, Develop and Commercialize CAR T Cell Immunotherapies [bluebird bio]

5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES

Novartis building out cell and gene therapy platform that'll lead the pack, CEO promises [Fierce Pharma]

TCR deal spree intensifies as Roche commits up to $2B in Adaptive Biotech to develop personalized cancer drugs [EndPoints]

5.12.6 IMMUNOTHÉRAPIES - AMM

Atezolizumab Approved for Initial Treatment of Metastatic Lung Cancer [NCI]

5.2 PHARMA

AstraZeneca announces organisational changes [AstraZeneca]

Top Cancer Doctor, Forced Out Over Ties to Drug Makers, Joins Their Ranks [NY Times]

AstraZeneca picks Baselga to lead oncology R&D in growth plan [Reuters]

5.2.2 PHARMA - FUSIONS & ACQUISITIONS

Eli Lilly Makes an $8B Cancer Genetics Bet with Loxo Acquisition [Xconomy]

JPM 2019: Bristol-Myers, Celgene CEOs trot out detailed case for $74B megadeal [Fierce Pharma]

JPM19: Lilly to buy Loxo Oncology for $8B [Biopharma Dive]

Lilly Announces Agreement To Acquire Loxo Oncology [Lilly]

Eli Lilly to buy Loxo Oncology for $8 billion in huge bet on cancer genetics [STAT]

5.3 TRAITEMENTS - FDA, EMA, NICE...

Human medicines: highlights of 2018 [EMA]

All seven of the FDA’s recent commissioners agree it should be independent — but not on how to accomplish it [STAT]

6.1 OBSERVATION

How important is medical care to life expectancy gains? [Healthcare Economist]

6.10 POLITIQUES

NHS 10-year plan: clear commitments for cancer, but no long-term fix for staff shortages [Cancer Research UK]

Cancer Research UK cautiously optimistic over the NHS England Long Term Plan [Cancer Research UK]

6.5 MÉDECINES ALTERNATIVES/COMPLÉMENTAIRES

China authorities arrest 18 at TCM firm after cancer case sparks outcry [Reuters]

6.7 DMP, BIG DATA & APPLIS

Here’s what scientists searched for in 2018: AI is up, stress is down [Nature]

6.7.1 IA/BIOINFORMATIQUE

High-performance medicine: the convergence of human and artificial intelligence [Nature Medicine]

6.9 CONTROVERSES

Latest trial in J&J talc litigations gets under way in California [Reuters]